Gastric Secretion in Zollinger-Ellison Syndrome: Correlation with Clinical Expression, Tumor Extent and Role in Diagnosis—A Prospective NIH Study of 235 Patients and a Review of 984 Cases in the Literature
The DOI matches its Crossref record.
Abstract
Introduction Abbreviations used in this article: BAC, basal acid H+ concentration, BAC/MAC, ratio of basal and maximal acid H+ concentration, BAO, basal acid output, CT, computed tomographic scan, MAC, maximal acid H+ concentration, MAO, maximal acid output, MEN1, multiple endocrine neoplasia-type 1, MRI, magnetic resonance imaging, NIH, National Institutes of Health, PPI, proton pump inhibitor, ZES, Zollinger-Ellison syndrome Since the initial description of Zollinger-Ellison syndrome (ZES) in 1955 (314), this disorder has been characterized by the presence of severe gastric acid hypersecretion and refractory peptic ulcer disease treatable only by total gastrectomy due to a non-beta islet cell tumor (75,132,133). Later it was demonstrated the tumor ectopically releases gastrin (that is, it is a gastrinoma) and the hypergastrinemia is responsible for the gastric acid hypersecretion (108,109,132,133,176). In the early descriptions of ZES by Zollinger, Ellison, and others, it was reported that gastric acid hypersecretion was a cardinal feature of this syndrome, with gastric outputs of several liters over a 12-hour period, associated with high concentrations of acid (100 mEq/L) (74,75,314,317). In fact, after the initial description of ZES, gastric acid secretory studies were the method of choice for the diagnosis of ZES (5,75,139,158,223,229,314). After gastrin was determined to be the causative hormone in ZES and it was shown that hypergastrinemia was present in almost all cases of ZES, assessment of fasting gastrin levels or performance of gastrin provocative tests became the initial study that led to the diagnosis of ZES in most patients (93,124,133,134,176,177,195,226,275,307). Currently, a number of factors continue to make assessing gastric acid secretion 1 of the requirements for the diagnosis of ZES (131,133,171,184,190,307). Gastric secretory testing is the only unequivocal means to distinguish physiologic from pathologic causes of hypergastrinemia (51,131,133,184,190,307). The current importance of gastric secretory testing is further increased because hypergastrinemia secondary to non-ZES causes (such as potent acid suppressant medications) is now common (144,148,233). In 60% of patients with ZES, fasting gastrin levels overlap with those in patients with other causes of gastric hypersecretion and hypergastrinemia (93,133). In these patients secretin provocative testing is the most commonly used study to determine whether ZES may be present (63,93,151,177). Unfortunately, secretin provocative tests can be negative in a significant proportion of patients with ZES—as high as 50% in some studies (53,93,154,273). Furthermore, recently it has not been possible to obtain secretin for gastrin provocative testing. Therefore, in patients with negative secretin provocative tests or no secretin testing, the level of the gastric hypersecretion combined with the presence of hypergastrinemia is increasingly important for the diagnosis of ZES. Despite its importance in the diagnosis of ZES, previous studies on gastric acid hypersecretion in this disorder provide limited information for a number of reasons. Most studies evaluating the sensitivity of the various proposed gastric acid secretory criteria for the diagnosis of ZES were done a number of years ago and may have significant limitations in regard to patients today. Most studies were performed before the full clinical spectrum of ZES was appreciated and established criteria were developed for its diagnosis. Therefore, in many of these older studies, patients without established ZES were included, or conversely, some cases that would be diagnosed as ZES today were not included. Patients were not categorized as to whether multiple endocrine neoplasia-type 1 (MEN1) was present or not, and whether gastric acid-reducing been performed and the of of the gastric acid secretory Furthermore, it was not in most studies that or and was established the the gastric acid secretory was the because in the older studies most patients with disease with of ZES and no gastric were gastric acid secretory were in patients with peptic ulcer the The of these factors is that in almost all gastric acid secretion in patients with ZES, only of patients were included. Therefore, the of various proposed acid secretory criteria for the diagnosis of ZES has been in patients with peptic ulcer patients with ZES were to determine the sensitivity of the various proposed Furthermore, because of the limited of patients no studies that have possible the various and tumor tumor and tumor with the of the gastric acid is important because the of gastric acid hypersecretion is reported to in patients the factors to this years ago a to study the and of was the National Institutes of The of this study of gastric acid hypersecretion in patients with ZES in this and with of patients from in the The of this study were to the clinical and with the of the gastric acid secretory studies to the causative to t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationGastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Self-citationNANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
Self-citation
Metadata
- Authors
- ROY, P. K., VENZON, D. J., FEIGENBAUM, K. M., KOVIACK, P. D., BASHIR, S., OJEABURU, J. V., GIBRIL, F., & JENSEN, R. T.
- Venue
- Medicine
- Published
- 2001-05
- Volume
- 80
- Issue
- 3
- Pages
- 189-222
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W1997342078
- Cited by
- 133
- References
- 0
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastric Secretion in Zollinger-Ellison Syndrome: Correlation with Clinical Expression, Tumor Extent and Role in Diagnosis—A Prospective NIH Study of 235 Patients and a Review of 984 Cases in the Literature. https://app.cochat.ai/papers/10.1097/00005792-200105000-00005
- The paper
- ROY, P. K., VENZON, D. J., FEIGENBAUM, K. M., KOVIACK, P. D., BASHIR, S., OJEABURU, J. V., GIBRIL, F., & JENSEN, R. T. (2001). Gastric Secretion in Zollinger-Ellison Syndrome: Correlation with Clinical Expression, Tumor Extent and Role in Diagnosis—A Prospective NIH Study of 235 Patients and a Review of 984 Cases in the Literature. Medicine. https://doi.org/10.1097/00005792-200105000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.